TB-500 (Thymosin Beta-4) mastery course
Unit 8 of 12
Clinical trials & human evidence
TB-500 stands out from most gray-market peptides because thymosin beta-4 has been through real human trials, run mainly…
What the actual human studies show
TB-500 stands out from most gray-market peptides because thymosin beta-4 has been through real human trials, run mainly by RegeneRx and its joint venture ReGenTree, including two dry-eye phase 3 trials of 601 and 700 patients. But "real trials" is not the same as "proven": as of 2026 no pivotal trial has produced a positive primary endpoint, and none of them tested the injected use that drives community demand.
This unit places the evidence on a ladder, walks the human safety and dry-eye data, and is honest about what those completed trials actually returned.